REFERENCES
1. Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636-48.
3. Montero S, Abrams D, Ammirati E, Huang F, et al. Fulminant myocarditis in adults: a narrative review. J Geriatr Cardiol. 2022;19:137-51.
4. Giordani AS, Baritussio A, Vicenzetto C, et al. Fulminant myocarditis: when one size does not fit all - a critical review of the literature. Eur Cardiol. 2023;18:e15.
5. Cipriani M, Merlo M, Gabrielli D, et al. ANMCO/SIC Consensus document on the management of myocarditis. G Ital Cardiol. 2020;21:969-89.
6. Jiang J, Shu H, Wang DW, et al. Chinese Society of Cardiology guidelines on the diagnosis and treatment of adult fulminant myocarditis. Sci China Life Sci. 2024;67:913-39.
7. Kociol RD, Cooper LT, Fang JC, et al. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation. 2020;141:6.
8. Rodríguez-Pintó I, Espinosa G, Erkan D, et al. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology. 2018;57:1264-70.
9. Drazner MH, Bozkurt B, Cooper LT, et al. 2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis: A report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2025;85:391-431.
10. Meani P, Lorusso R, Pappalardo F. ECPella: concept, physiology and clinical applications. J Cardiothorac Vasc Anesth. 2022;36:557-66.




